Bharat Biotech enters into partnership with Biofabri for TB vaccine

This partnership will guarantee the supply of tuberculosis (TB) vaccines in more than 70 countries, especially in Southeast Asia and sub-Saharan Africa


Bharat Biotech | Tuberculosis

Bharat Biotech on Wednesday said it has entered into a partnership with Biofabri, a Spanish biopharmaceutical firm, for the development, manufacturing and marketing of a new tuberculosis vaccine.

This partnership will guarantee the supply of tuberculosis (TB) vaccines in more than 70 countries, especially in Southeast Asia and sub-Saharan Africa, with a high TB incidence, the company said in a statement.

The new TB vaccine, ‘MTBVAC’, is being manufactured and developed by Biofabri, in close collaboration with the University of Zaragoza, IAVI and the Tuberculosis Vaccine Initiative (TBVI).

“This agreement between Bharat Biotech and Biofabri would guarantee the worldwide production and the supply of the future vaccine in more than 70 countries with a high TB incidence, such as India which has the highest TB burden in the world, with a 25 per cent of all cases,” the company said.

Bharat Biotech Chairman and Managing Director Krishna Ella said, “We are proud to announce this partnership with BioFabri, where MTBVAC can become a global TB vaccine.”

Bharat Biotech has opted for this vaccine candidate owing to its advanced stage of clinical development as well as the promising results from Phase-I and Phase-II clinical trials, he added.

The Phase-III clinical trials are expected to start in Senegal, South Africa and Madagascar in the second half of 2022, the company said.

Biofabri CEO Esteban Rodrguez said the agreement with Bharat Biotech is a milestone in the MTBVAC project.

Right from Day 1, the company’s goal has been to make a vaccine accessible to everyone at affordable prices in middle and low-income countries where the incidence of tuberculosis is high, Rodrguez added.

“The contract signed with Bharat Biotech ensures that our vaccine reaches countries such as India, Indonesia, the Philippines, Pakistan and South Africa, among others, where tuberculosis is a public health problem due to its high incidence,” Rodrguez said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor